{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T21:36:25Z","timestamp":1793568985579,"version":"4.5.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Atypical chronic myeloid leukemia (aCML), <jats:italic toggle=\"yes\">BCR-ABL1<\/jats:italic>-negative, is a rare myelodysplastic\/myeloproliferative neoplasm (MDS\/MPN) characterized by leukocytosis, granulocytic dysplasia, and typically poor patient outcomes. Since its first description as a variant CML lacking the Philadelphia chromosome (Ph), the diagnostic criteria for aCML have evolved significantly. Nevertheless, distinguishing it from other Ph-negative myeloid neoplasms can still be very challenging, and given its generally worse prognosis, this is a clinically important distinction. The purpose of this review is to conceptualize our understanding of aCML molecular genetics based on recent advances, and describe how genetic features can be used in conjunction with clinical and morphologic features to better diagnose this elusive entity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>The classification criteria for aCML have evolved and changed multiple times over the past decades, and is now based on strict application of morphologic, clinical and laboratory criteria. Recent work has elucidated the mutational landscape of aCML, especially with respect to potentially differentiating profiles compared with other Ph-negative myeloid neoplasms.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Atypical CML is a rare MDS\/MPN overlap syndrome that can be diagnostically challenging; however, its emerging molecular genetic understanding and clinicomorphologic phenotype can help in distinguishing it from other Ph-negative myeloid neoplasms.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/moh.0000000000000565","type":"journal-article","created":{"date-parts":[[2020,1,5]],"date-time":"2020-01-05T23:27:03Z","timestamp":1578266823000},"page":"122-127","source":"Crossref","is-referenced-by-count":7,"title":["Distinguishing atypical chronic myeloid leukemia from other Philadelphia-negative chronic myeloproliferative neoplasms"],"prefix":"10.1097","volume":"27","author":[{"given":"Sam","family":"Sadigh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Hasserjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20231211","first-page":"87","article-title":"Atypical chronic myeloid leukaemia, BCR-ABL1 negative","author":"Orazi","year":"2017","journal-title":"WHO Classification of tumors of haematopoietic and lymphoid tissues"},{"key":"R2-20231211","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/1097-0142(19861101)58:9<2023::AID-CNCR2820580912>3.0.CO;2-H","article-title":"Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia","volume":"58","author":"Kantarjian","year":"1986","journal-title":"Cancer"},{"key":"R3-20231211","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1200\/JCO.2001.19.11.2915","article-title":"BCR rearrangement-negative chronic myelogenous leukemia revisited","volume":"19","author":"Kurzrock","year":"2001","journal-title":"J Clin Oncol"},{"key":"R4-20231211","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/2040620715607416","article-title":"Characteristics and survival of BCR\/ABL negative chronic myeloid leukemia: a retrospective analysis of the Surveillance, Epidemiology and End Results database","volume":"6","author":"Giri","year":"2015","journal-title":"Ther Adv Hematol"},{"key":"R5-20231211","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/bjh.14619","article-title":"Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working party of the European Society for Blood and Bone Marrow Transplantation","volume":"177","author":"Onida","year":"2017","journal-title":"Br J Haematol"},{"key":"R6-20231211","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.leukres.2018.11.003","article-title":"Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: a retrospective nationwide study in Japan","volume":"75","author":"Itonaga","year":"2018","journal-title":"Leuk Res"},{"key":"R7-20231211","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.3324\/haematol.2014.113159","article-title":"Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia","volume":"99","author":"Meggendorfer","year":"2014","journal-title":"Haematologica"},{"key":"R8-20231211","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","article-title":"Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"R9-20231211","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/ajh.24722","article-title":"Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia","volume":"92","author":"Patnaik","year":"2017","journal-title":"Am J Hematol"},{"key":"R10-20231211","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/978-3-319-62146-3_11","article-title":"Atypical chronic myeloid leukemia, BCR\/ABL1 negative","author":"Levinson","year":"2018","journal-title":"Precision molecular pathology of myeloid neoplasms, Molecular Pathology Library"},{"key":"R11-20231211","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N Engl J Med"},{"key":"R12-20231211","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ng.2495","article-title":"Recurrent SETBP1 mutations in atypical chronic myeloid leukemia","volume":"45","author":"Piazza","year":"2013","journal-title":"Nat Genet"},{"key":"R13-20231211","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/leu.2013.133","article-title":"SETBP1 mutations occur in 9% of MDS\/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations","volume":"27","author":"Meggendorfer","year":"2013","journal-title":"Leukemia"},{"key":"R14-20231211","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2014-06-579466","article-title":"Recurrent ETNK1 mutations in atypical chronic myeloid leukemia","volume":"125","author":"Gambacorti-Passerini","year":"2015","journal-title":"Blood"},{"key":"R15-20231211","first-page":"256","article-title":"The mutational landscape of atypical chronic myeloid leukemia","volume":"18","author":"Langabeer","year":"2019","journal-title":"EXCLI J"},{"key":"R16-20231211","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.blre.2018.07.004","article-title":"Current and evolving understanding of atypical chronic myeloid leukemia","volume":"33","author":"Schwartz","year":"2019","journal-title":"Blood Rev"},{"key":"R17-20231211","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/cam4.1946","article-title":"Comprehensive mutation profiling and mRNA expression analysis in atypical chronic myeloid leukemia in comparison with chronic myelomonocytic leukemia","volume":"8","author":"Faisal","year":"2019","journal-title":"Cancer Med"},{"key":"R18-20231211","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/blood.2019000611","article-title":"Genomic landscape of neutrophilic leukemias of ambiguous diagnosis","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood"},{"key":"R19-20231211","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood.2019002302","article-title":"Illuminating neutrophilic myeloid neoplasms","volume":"134","author":"Hasserjian","year":"2019","journal-title":"Blood"},{"key":"R20-20231211","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000046641","article-title":"Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta","volume":"107","author":"Steer","year":"2002","journal-title":"Acta Haematol"},{"key":"R21-20231211","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1600-0609.2012.01799.x","article-title":"Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement","volume":"89","author":"Arefi","year":"2012","journal-title":"Eur J Haematol"},{"key":"R22-20231211","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1182\/blood-2014-02-555607","article-title":"Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib","volume":"123","author":"Cheah","year":"2014","journal-title":"Blood"},{"key":"R23-20231211","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood-2016-08-693630","article-title":"How I treat atypical chronic myeloid leukemia","volume":"129","author":"Gotlib","year":"2017","journal-title":"Blood"},{"key":"R24-20231211","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2012-01-404863","article-title":"SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)","volume":"120","author":"Meggendorfer","year":"2012","journal-title":"Blood"}],"container-title":["Current Opinion in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOH.0000000000000565","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T19:01:45Z","timestamp":1702321305000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOH.0000000000000565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/moh.0000000000000565","relation":{},"ISSN":["1065-6251","1531-7048"],"issn-type":[{"value":"1065-6251","type":"print"},{"value":"1531-7048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}